Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Macrophages are required for neonatal heart regeneration
Arin B. Aurora, … , Hesham A. Sadek, Eric N. Olson
Arin B. Aurora, … , Hesham A. Sadek, Eric N. Olson
Published February 24, 2014
Citation Information: J Clin Invest. 2014;124(3):1382-1392. https://doi.org/10.1172/JCI72181.
View: Text | PDF
Research Article Article has an altmetric score of 32

Macrophages are required for neonatal heart regeneration

  • Text
  • PDF
Abstract

Myocardial infarction (MI) leads to cardiomyocyte death, which triggers an immune response that clears debris and restores tissue integrity. In the adult heart, the immune system facilitates scar formation, which repairs the damaged myocardium but compromises cardiac function. In neonatal mice, the heart can regenerate fully without scarring following MI; however, this regenerative capacity is lost by P7. The signals that govern neonatal heart regeneration are unknown. By comparing the immune response to MI in mice at P1 and P14, we identified differences in the magnitude and kinetics of monocyte and macrophage responses to injury. Using a cell-depletion model, we determined that heart regeneration and neoangiogenesis following MI depends on neonatal macrophages. Neonates depleted of macrophages were unable to regenerate myocardia and formed fibrotic scars, resulting in reduced cardiac function and angiogenesis. Immunophenotyping and gene expression profiling of cardiac macrophages from regenerating and nonregenerating hearts indicated that regenerative macrophages have a unique polarization phenotype and secrete numerous soluble factors that may facilitate the formation of new myocardium. Our findings suggest that macrophages provide necessary signals to drive angiogenesis and regeneration of the neonatal mouse heart. Modulating inflammation may provide a key therapeutic strategy to support heart regeneration.

Authors

Arin B. Aurora, Enzo R. Porrello, Wei Tan, Ahmed I. Mahmoud, Joseph A. Hill, Rhonda Bassel-Duby, Hesham A. Sadek, Eric N. Olson

×

Figure 4

Depletion of monocytes/macrophages blocks heart regeneration in neonatal mice.

Options: View larger image (or click on image) Download as PowerPoint
Depletion of monocytes/macrophages blocks heart regeneration in neonatal...
(A) At 7 days after MI, H&E-stained serial heart sections, starting below the ligature and progressing toward the apex (3 sections per heart), show a diminishing infarct area that has been displaced to the periphery in control mice. Cl2MDP-L–treated mice maintain an interstitial scar. The injured area is circled. Scale bar: 1 mm. (B) Masson’s trichrome staining of serial sections, starting below the ligature and progressing toward the apex, from control or Cl2MDP-L–treated mice 21 days following MI at P1 to visualize fibrosis. The injured area is circled. Scale bar: 1 mm. (C and D) Picrosirius red staining on heart sections from control or Cl2MDP-L–treated mice 21 days following MI at P1. (C) Representative images and (D) quantification as a percentage of total section area (≥7 sections per heart) show significantly more fibrosis in the Cl2MDP-L–treated group (n = 7–8 mice per group). Scale bar: 1 mm. (E) Cardiac function following MI or sham surgeries was assessed at 28 days after MI by echocardiography. Data are expressed as the percentage of FS (n = 3–4 mice per group). Data are mean ± SEM. *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Posted by 6 X users
Referenced in 4 patents
On 1 Facebook pages
Mentioned in 1 Google+ posts
Referenced in 1 clinical guideline sources
651 readers on Mendeley
1 readers on CiteULike
See more details